In a groundbreaking shift for medical research, the United Kingdom has dramatically reduced the time it takes to approve clinical trials, cutting the average review period from a lengthy 91 days to an impressive 41 days. This remarkable achievement, driven by the integration of artificial
Neuroblastoma, a devastating cancer affecting primarily children under five, stands as one of the most aggressive solid tumors in pediatric populations, with high-risk cases often showing dismal outcomes despite rigorous treatments. With only about half of these young patients achieving a cure
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research and development, coupled with a keen understanding of tech and innovation, has positioned him at the forefront of groundbreaking advancements in cancer treatment. Today, we’re diving into
The biotechnology sector often rides a rollercoaster of high hopes and sharp setbacks, and few cases illustrate this better than the recent plunge in Exelixis’ stock value following the release of data from its STELLAR-303 trial. Focused on zanzalintinib, an experimental drug for metastatic
As we dive into the complex world of healthcare policy, I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose deep understanding of technology and innovation in the industry, coupled with extensive experience in research and development, offers invaluable insights. Today,
Imagine a world where the brain's fundamental energy processes, long thought to be set in stone, are suddenly redefined by a single discovery that could alter the course of treatment for devastating neurological conditions. Researchers from prestigious institutions have recently unveiled a
